BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25316052)

  • 1. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer.
    Jenkinson C; Elliott V; Menon U; Apostolidou S; Fourkala OE; Gentry-Maharaj A; Pereira SP; Jacobs I; Cox TF; Greenhalf W; Timms JF; Sutton R; Neoptolemos JP; Costello E
    J Proteomics; 2015 Jan; 113():400-2. PubMed ID: 25316052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer.
    Prokopchuk O; Grünwald B; Nitsche U; Jäger C; Prokopchuk OL; Schubert EC; Friess H; Martignoni ME; Krüger A
    BMC Cancer; 2018 Feb; 18(1):128. PubMed ID: 29394913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble stroma-related biomarkers of pancreatic cancer.
    Resovi A; Bani MR; Porcu L; Anastasia A; Minoli L; Allavena P; Cappello P; Novelli F; Scarpa A; Morandi E; Falanga A; Torri V; Taraboletti G; Belotti D; Giavazzi R
    EMBO Mol Med; 2018 Aug; 10(8):. PubMed ID: 29941541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer.
    Joergensen MT; Brünner N; De Muckadell OB
    Anticancer Res; 2010 Feb; 30(2):587-92. PubMed ID: 20332475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
    Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
    Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.
    Jenkinson C; Elliott VL; Evans A; Oldfield L; Jenkins RE; O'Brien DP; Apostolidou S; Gentry-Maharaj A; Fourkala EO; Jacobs IJ; Menon U; Cox T; Campbell F; Pereira SP; Tuveson DA; Park BK; Greenhalf W; Sutton R; Timms JF; Neoptolemos JP; Costello E
    Clin Cancer Res; 2016 Apr; 22(7):1734-1743. PubMed ID: 26573598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
    Tonack S; Jenkinson C; Cox T; Elliott V; Jenkins RE; Kitteringham NR; Greenhalf W; Shaw V; Michalski CW; Friess H; Neoptolemos JP; Costello E
    Br J Cancer; 2013 May; 108(9):1846-53. PubMed ID: 23579209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Huerter LM; Scaife CL; Emerson LL; Boucher KM; Jones KA; Mulvihill SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2605-10. PubMed ID: 20729288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma.
    Ren YQ; Zhang HY; Su T; Wang XH; Zhang L
    Eur Rev Med Pharmacol Sci; 2014 Oct; 18(20):3063-8. PubMed ID: 25392106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
    Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
    Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
    Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
    Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
    Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
    BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of adhesion molecules ICAM-1 and VCAM-1 and tissue inhibitor of metalloproteinases, TIMP-1, are elevated in patients with autoimmune thyroid disorders: relevance to vascular inflammation.
    Jublanc C; Beaudeux JL; Aubart F; Raphael M; Chadarevian R; Chapman MJ; Bonnefont-Rousselot D; Bruckert E
    Nutr Metab Cardiovasc Dis; 2011 Oct; 21(10):817-22. PubMed ID: 20685094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
    Parikh DA; Durbin-Johnson B; Urayama S
    J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.